D-0567-2025 Class II Ongoing

Recalled by Direct Rx — Dawsonville, GA

FDA drug recall D-0567-2025 was initiated by Direct Rx on Mar 7, 2025 and is designated Class II. Reason for recall: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. The recall status is ongoing. Affected quantity: 16 bottles.

Recall details

Product Type
Drugs
Report Date
Aug 13, 2025
Initiation Date
Mar 7, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
16 bottles

Product description

Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, NDC 61919-422-30

Reason for recall

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

Distribution pattern

Nationwide

Code information

Lot #: 02AU2406, Exp 01/31/2027

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0567-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0567-2025. Report a data issue: hello@regdatalab.com.